

blood

2001 98: 428-435
doi:10.1182/blood.V98.2.428

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

Klaus Podar, Yu-Tzu Tai, Faith E. Davies, Suzanne Lentzsch, Martin Sattler, Teru Hideshima, Boris K. Lin, Deepak Gupta, Yoshihito Shima, Dharminder Chauhan, Constantine Mitsiades, Noopur Raje, Paul Richardson and Kenneth C. Anderson

Updated information and services can be found at:

<http://bloodjournal.hematologylibrary.org/cgi/content/full/98/2/428>

Articles on similar topics may be found in the following *Blood* collections:

[Neoplasia](#) (4217 articles)

[Signal Transduction](#) (1930 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:

<http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington DC 20036.

Copyright 2007 by The American Society of Hematology; all rights reserved.



Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

Klaus Podar, Yu-Tzu Tai, Faith E. Davies, Suzanne Lentzsch, Martin Sattler, Teru Hideshima, Boris K. Lin, Deepak Gupta, Yoshihito Shima, Dharminder Chauhan, Constantine Mitsiades, Noopur Raje, Paul Richardson, and Kenneth C. Anderson

Multiple myeloma (MM) remains incurable, with a median survival of 3 to 4 years. This study shows direct effects of vascular endothelial growth factor (VEGF) upon MM and plasma cell leukemia (PCL) cells. The results indicate that VEGF triggers tumor cell proliferation via a protein kinase C (PKC)-independent Raf-1-MEK-extracellular signal-regulated protein kinase pathway, and migration via a PKC-dependent pathway. These observations provide the framework for novel therapeutic strategies targeting VEGF signaling cascades in MM. (Blood. 2001;98:428-435)

© 2001 by The American Society of Hematology

Introduction

Multiple myeloma (MM) is characterized by the clonal proliferation of malignant plasma cells in the bone marrow (BM) associated with bone loss, renal disease, and immunodeficiency. Malignant transformation in MM progresses from immortalization of plasma cells (monoclonal gammopathy of undetermined significance [MGUS]) to the establishment of MM in the BM with evolution of growth-factor-independent growth and resistance to apoptosis.¹ Despite recent new insights into the pathogenesis of MM, it remains incurable with a median survival of approximately 3 to 4 years. New biologically based therapies are therefore urgently needed.

The various growth factors belonging to the vascular endothelial growth factor (VEGF) family (VEGF, placenta growth factor [PlGF], VEGF-B, VEGF-C, and VEGF-D) act as modulators and inducers of angiogenesis *in vivo*.²⁻⁴ The active forms of VEGF are synthesized either as homodimers^{5,6} or as heterodimers with other VEGF family members, such as PlGF.⁷ Five molecular forms of VEGF are generated by alternative splicing of its RNA transcripts: VEGF₁₂₁, VEGF₁₄₅, VEGF₁₆₅, VEGF₁₈₉, and VEGF₂₀₆. These forms differ primarily in the presence or absence of heparin and heparan-sulfate binding domains, encoded by exons 6 and 7.⁸ The VEGF₁₂₁, VEGF₁₆₅, and VEGF₁₈₉ forms are abundant and usually produced simultaneously,² whereas VEGF₁₄₅ is less common and produced by cells derived from the female reproductive system,⁹ penis, and kidney.^{10,11} Recently VEGF₁₄₅ has also been found in primary effusion lymphomas (PELs) associated with Kaposi sarcoma-associated herpesvirus (or human herpesvirus-8) infection, as well as in prostate carcinoma.¹²

In solid tumors, VEGF has an important role in the induction of neovascularization correlating with tumor growth and metastatic potential.¹³⁻¹⁷ However, recent studies also suggest a role for VEGF in hematological malignancies. In MM, for example VEGF is expressed and secreted by tumor cells as well as BM stromal cells (BMSCs).^{18,19} It may account, at least in part, for the increased

microvessel density (MVD) that has been observed in the BM of patients with MM and that correlates with disease progression and poor prognosis.²⁰⁻²² These data, coupled with the known antiangiogenic properties of thalidomide (Thal),²³ provided the rationale for the use of Thal to treat MM. Remarkable clinical responses to Thal were observed in 32% of MM patients whose disease was refractory to conventional and high-dose therapy.²⁴ We suggested at the time that the anti-MM activity of Thal against MM may not only be related to inhibition of VEGF-induced BM angiogenesis, but might also include blocking of VEGF-induced direct effects on MM cell growth, survival, and migration.²⁵

The present study shows for the first time that VEGF induces proliferation and triggers migration of human MM cells, suggesting an autocrine VEGF loop in MM. Exogenous VEGF₁₆₅ activates at least 2 signaling pathways in MM: the Raf-1-MEK-extracellular signal-regulated protein kinase (ERK) pathway mediating proliferation, and a protein kinase C (PKC)-dependent cascade associated with migration. These observations provide the framework for novel therapeutic strategies targeting VEGF in MM.

Materials and methods

Cells and cell culture

The human MM cell line MM.1S (dexamethasone-sensitive),²⁷ patient MM cells, and patient plasma cell leukemia (PCL) cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, 10 µg/mL streptomycin, and 2 mM L-glutamine. Human umbilical vein endothelial cells (HUVECs), purchased from Clonetics Biowhittaker (Walkersville, MD) (HUVEC P168) were maintained in EGM-2MV media (Clonetics Biowhittaker).

Isolation of patient's tumor cells

Mononuclear cells were obtained by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) separation from peripheral blood samples of a patient

From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA.

Submitted October 31, 2000; accepted March 27, 2001.

Supported by National Institutes of Health grant PO-1 78378, and the Doris Duke Distinguished Clinical Research Scientist Award (K.C.A.).

F.E.D. and S.L. contributed equally to this work.

Reprints: Kenneth C. Anderson, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: kenneth_anderson@dfci.harvard.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2001 by The American Society of Hematology

with PCL. MM patient cells (96% CD38⁺CD45RA⁻) were purified from patient BM samples, as previously described.³⁶

Reverse-transcriptase polymerase chain reaction analyses of VEGF and VEGF-receptors

Total RNA was prepared with Trizol Reagent (Gibco Life Technologies, Rockville, MD) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized by means of SuperScript One-Step reverse-transcriptase polymerase chain reaction (RT-PCR) system with Platinum Taq (Gibco Life Technologies). VEGF primers 5'-TCG GGC CTC CGA AAC CAT GA-3' (sense) and 5'-CCT GGT GAG AGA TCT GGT TC-3' (antisense), corresponding to sequences in the 3' and 5' untranslated regions, were used to amplify the known splice variants: 516 base pairs (bp) of VEGF₁₂₁; 588 bp of VEGF₁₄₅; 648 bp of VEGF₁₆₅; 720 bp of VEGF₁₈₉; and 771 bp of VEGF₂₀₆. The thermal cycle profile consisted of denaturing at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute. The samples were amplified for 35 cycles. VEGF receptor sense primer 5'-CAA GTG GCC AGA GGC ATG GAG TT-3' (corresponding to nucleotides +3262 to +3284) and antisense primer 5'-GAT GTA GTC TTT ACC ATC CTG TTG-3' (corresponding to nucleotides +3736 to +3759) were used for the amplification of Fms-like tyrosine kinase-1 (Flt-1)³⁷; 5'-CAA CAA AGT CGG GAG AGG AG-3' (sense) and 5'-ATG ACG ATG GAC AAG TAG CC-3' (antisense) were used for amplification of kinase insert domain-containing receptor (KDR).¹⁸ The thermal cycle profile consisted of denaturing at 94°C for 1 minute, annealing at 60°C for 2 minutes, and extension at 72°C for 3 minutes. The samples were amplified for 32 cycles. We used 20 pg primers. The integrity of messenger RNA of all samples was confirmed by amplification of β-actin. PCR products were separated on a 1% agarose gel and photographed.

Enzyme-linked immunosorbent assay

Cells were seeded onto 6-well plates at a concentration of 1×10^6 cells per well in RPMI 1640 with 1% FBS. After 48 hours, the supernatants were collected and analyzed by VEGF-enzyme-linked immunosorbent assays (ELISAs) (R&D Systems, Minneapolis, MN). Briefly, 96-well plates were coated with anti-human VEGF antibody overnight, rinsed, and blocked with 300 μL phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), 5% sucrose, and 0.05% NaN₃ for 2 hours. After washing, 100 μL of sample or standards diluted in Tris-Cl, 0.1% BSA, and 0.05% Tween 20 (pH 7.3) were added to the wells and incubated for 2 hours at room temperature (RT). The cells were rinsed again, and biotinylated anti-human VEGF antibody was added for 2 hours at RT. After a further washing step, the wells were incubated with streptavidin horseradish peroxidase for 20 minutes at RT and rinsed again. The reaction was started by the addition of 100 μL H₂O₂ and tetramethylbenzidine for 30 minutes at RT. After stopping the reaction with 1 M H₂SO₄, the optical density of each well was detected by means of a microtiter plate reader at 450 nm. Each well was analyzed in triplicate.

Stimulation of cells

For signaling experiments, cells were starved for 15 to 18 hours prior to stimulation with 100 ng/mL VEGF (recombinant human VEGF) (R&D) in medium with 1% FBS overnight and then for 3 hours without FBS. For proliferation assays, cells were starved for 3 hours prior to stimulation with different concentrations of VEGF in medium with 1% to 5% FBS and cultured in starvation medium for 72 hours.

DNA synthesis and cell proliferation assay

Cell growth was assessed by the addition of 0.5 μCi [³H] thymidine per well during the last 9 hours of a 72-hour culture at 37°C. Radioactive labeling was determined by harvesting the cells onto glass-fiber filtermats with an automatic cell harvester (Tomec Harvester 96 Mach III, Hamden, CT) and counting using the Wallac Trilux Betaplate scintillation counter (Turku, Finland).

Cell lysis, immunoprecipitation, and Western blot analysis

Cells were washed 3 times with PBS and lysed with either lysis buffer (10 mM Tris, 50 mM NaCl, Na-pyrophosphate, 1% triton, 1 mM sodium vanadate, 1 mM phenylmethyl sulfonyl fluoride, and protein inhibitor cocktail) (Boehringer Mannheim, Germany) or radioimmunoprecipitation assay lysis buffer. Insoluble material was removed by centrifugation (15 000 rpm for 30 minutes at 4°C). Immunoprecipitation was performed as described previously.³⁸ Briefly, Flt-1 (H-225) and fetal liver kinase-1 (Flk-1) (C-1158) (Santa Cruz Biotechnology, CA) Abs were used to immunoprecipitate Flt-1 and Flk-1, respectively. Immunocomplexes were collected following overnight incubation at 4°C with protein A-Sepharose beads (Sigma, St Louis, MO). For Western blotting, cell lysates (30 to 100 μg per lane) or immunoprecipitates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis prior to electrophoretic transfer onto Hybond C super (Amersham, Arlington Heights, IL). The blots were probed with Flt-1, Flk-1, Raf-1, phospho-tyrosine-specific 4G10, phospho-ERK, ERK-2, phospho-stress activated protein kinase (SAPK)/c-Jun NH₂-terminal kinase (JNK), phospho-p38, p38, phospho-signal transducer and activator of transcription 3 (phospho-STAT 3), and STAT 3 antisera prior to incubation with horseradish peroxidase-conjugated secondary antibodies and exposure to the enhanced chemiluminescence substrate.

Transwell migration assay

Cell migration was assayed by means of a modified Boyden chamber assay, as described previously.^{39,40} Briefly, starved cells were added on an 8-μm pore size polycarbonate membrane precoated with fibronectin separating the 2 chambers of a 6.5-mm transwell (Costar). VEGF (0.5 to 500 ng/mL), with or without the PKC inhibitor bisindolylmaleimide I, hydrochloride (BIM) (Calbiochem, San Diego, CA) was added to the lower chamber. After 2 to 5 hours, cells that migrated into the lower compartment were counted by means of a Coulter counter ZBII (Coulter Electronics, Bedfordshire, England).

Statistical analysis

Statistical significance of differences observed in VEGF-treated versus control cultures was determined by means of an unpaired Student *t* test. The minimal level of significance was $P < .05$.

Results

VEGF is present in the BM micro-environment of patients with MM and associated with the neovascularization at sites of MM cell infiltration.²⁶ In addition, VEGF is produced by MM cells and triggers interleukin (IL)-6 production from BMSCs, thereby augmenting MM cell growth and survival.¹⁹ In this study, we examined whether VEGF also has direct effects on MM cells. As a model system, we used a dexamethasone-sensitive (MM.1S) human MM cell line,²⁷ as well as patient MM and patient PCL cells.

Expression and secretion of VEGF isoforms in MM.1S, patient MM, and patient PCL cells

VEGF is expressed and secreted in MM cell lines, including RPMI 8226, ARH-77, U266, IM-9, and OPM-2,^{18,19} as well as in BMSCs. In the first series of experiments, we performed RT-PCR analysis to determine whether MM.1S cells, as well as patient MM and patient PCL cells, synthesize VEGF. As shown in Figure 1A, 3 predominant bands corresponding to the splice variants VEGF₁₂₁ (516 bp), VEGF₁₄₅ (588 bp), and VEGF₁₆₅ (648 bp) were produced by MM.1S, patient MM, and patient PCL cells, respectively.

To assess whether MM.1S, patient MM, and patient PCL cells secrete VEGF protein, cells were seeded onto 6-well plates at a




Figure 1. Expression and secretion of VEGF isoforms in MM.1S, patient MM, and patient PCL cells. (A) MM.1S, patient MM, and patient PCL cells express VEGF. Equal amounts of RNA were reverse transcribed to generate cDNA, which was subjected to VEGF-specific PCR amplification by means of paired primers as described in "Materials and methods." Three splice variants coding for the secreted isoforms VEGF₁₂₁ (516 bp), VEGF₁₄₅ (588 bp), and VEGF₁₆₅ (648 bp) were amplified from all cells. The quality of RNA was confirmed by RT-PCR amplification of β-actin. MWM indicates molecular weight marker. (B) MM.1S, patient MM cells, and patient PCL cells secrete VEGF. Supernatants from equal numbers of cells (1×10^6) were collected after 48 hours and analyzed for VEGF protein by ELISA.

concentration of 1×10^6 cells per well in RPMI 1640 with 1% FBS. VEGF secreted by these tumor cells was measured in 48-hour culture supernatants by ELISA. VEGF secretion ranged from 100 pg/mL (PCL cells) to 1000 pg/mL (MM cells) (Figure 1B). Taken together, these data show that MM.1S cells, patient MM cells, and patient PCL cells both synthesize and secrete VEGF.

VEGF induces proliferation in MM cells

To determine whether VEGF has direct effects on MM cells, we first examined whether VEGF₁₆₅ induced DNA synthesis in growth-factor–deprived MM.1S and patient MM cells. As shown in Figure 2A, VEGF induced a reproducible dose-dependent increase (2-fold) in proliferation in MM.1S cells assayed by [³H] thymidine uptake. To judge the biological significance of this finding, we subsequently studied the effect of VEGF on the proliferation of patient MM cells derived from 5 patients. As shown in Figure 2B, VEGF also induced a dose-dependent increase (1.3- to 1.4-fold) in proliferation in these cells.

VEGF triggers migration of MM and PCL cells

Since it was recently reported that VEGF stimulates migration of monocytes and macrophages,²⁸⁻³⁰ we next examined whether VEGF also triggers migration in MM.1S, patient MM, and patient PCL cells. Cell migration was assayed by measuring the transfilter migration activity of MM.1S cells seeded on membranes precoated with fibronectin. The addition of VEGF to conditioned medium in the lower chamber induced a dose-dependent cell migration of growth-factor–deprived MM.1S cells, patient MM cells, and patient PCL cells in the upper transwell chamber. Maximal activation of migration in MM.1S cells (2-fold) and patient MM

cells (3-fold) was induced by 5 ng/mL VEGF₁₆₅ (Figure 3A-B), whereas maximal activation of migration in patient PCL cells (approximately 250-fold) was induced by 50 ng/mL VEGF₁₆₅ (Figure 3C). VEGF₁₆₅ (5 ng/mL) markedly enhanced the migration in patient PCL cells (approximately 100-fold) relative to MM.1S cells, suggesting an important role of VEGF in the transition of MM to PCL.

Flt-1 is expressed and activated by VEGF in MM cells

We next sought to identify signaling pathways mediating these effects. Comparable transcript and protein expression of high-affinity VEGF receptor (VEGFR)–1/Flt-1 were detected by RT-PCR and immunoprecipitation, respectively, in MM.1S, patient MM cells, and patient plasma cells (data not shown). Despite low-level expression of Flt-1, VEGF triggered an up-regulation of tyrosine phosphorylation of Flt-1 in MM cell line MM.1S cells (Figure 4A).

Flt-1 immunoprecipitates of whole cell lysates of VEGF-stimulated HUVECs immunoblotted for Flt-1 served as a positive control. Reprobing of the membrane with antisera directed against Flt-1 confirmed equal protein loading. In contrast, KDR/VEGFR-2 the human homolog of Flk-1, was not detected (data not shown). Taken together, these data suggest that Flt-1 is a functional signaling receptor for VEGF in MM.1S cells.

VEGF activates the Raf–MEK–ERK pathway

We next sought to identify signaling molecules downstream of the receptor activated by VEGF. The activation of ERK-1 and ERK-2 mediates DNA-synthesis,^{31,32} and we have shown that IL-6–induced proliferation of MM cells is mediated by this pathway.³³ To




Figure 2. Effect of VEGF on MM cell proliferation. MM.1S (panel A) and MM cells isolated from 5 patients (panel B) (3×10^4 cells per well) were cultured in RPMI 1640 medium with 5% (MM.1S) or 10% (patient MM cells) FBS in 96-well assay plates. The cells were then either left untreated or treated with 1 to 1000 ng/mL of VEGF₁₆₅. Cell growth was assessed by addition of 0.5 μCi [³H] thymidine [³H (dT)] per well during the last 9 hours of 72-hour cultures at 37°C. Radioactive labeling was determined by harvesting the cells onto glass-fiber filtermats with an automatic cell harvester (Tomec Harvester 96 Mach III) and counting by means of the Wallac Trilux Betaplate scintillation counter. Data represent means and SDs for triplicate samples. Statistical significance for the proliferation of MM.1S cells was determined by analysis of variance followed by an unpaired Student *t* test: **P* < .005; ***P* < .001, as compared with control (without VEGF).




Figure 3. Effect of VEGF on MM and PCL cell migration. VEGF activates cell migration in MM and PCL cells. Growth-factor–deprived MM.1S (panel A), patient MM (panel B), and patient PCL (panel C) cells were plated on a polycarbonate membrane (8- μ m pore size) in a modified Boyden chamber and exposed for 4 hours to VEGF (0.5 to 500 ng/mL) added to the lower chamber. At the end of the treatments, cells on the lower part of the membrane were counted with a Coulter counter ZBII. The results shown for MM.1S cells are representative of 3 independent experiments.

assess whether VEGF activates ERK in MM cells, we starved MM.1S, patient MM cells, and patient PCL cells overnight in RPMI 1640 with 1% FBS and then for 3 hours in RPMI 1640 with no FBS. In time-course stimulation experiments, 100 ng/mL VEGF₁₆₅ triggered specific phosphorylation of ERK-1 and ERK-2 in MM.1S cells, in patient MM cells, and in patient PCL cells (Figure 4B). Equivalent amounts of ERK protein were confirmed by immunoblotting with anti-ERK-2 antibody. ERK phosphorylation, quantitated by densitometry, demonstrated variations in the time of maximal activation (Figure 4C). Similar results were observed in Hs Sultan and RPMI-8226 MM cells (data not shown).

To confirm that VEGF triggers ERK activation, we used anti-human VEGF antibody (anti-VEGF) (R&D) to neutralize human VEGF bioactivity, as well as PD98059 as a specific MEK-1 inhibitor. As can be seen in Figure 5B, VEGF-induced ERK phosphorylation in MM.1S and patient MM cells (Figure 5A) was inhibited by 60-minute pretreatment with anti-VEGF antibody (Figure 5A), confirming specific VEGF signaling. ERK phosphorylation by VEGF was also inhibited by 60-minute pretreatment with PD98059 (Figure 5C), implicating MEK-1 in VEGF signal transduction in MM cells (Figure 5C). We further observed that VEGF induced electric mobility shifting of the MEK kinase Raf-1, consistent with Raf-1 activation, which was abrogated by anti-VEGF antibody (data not shown).

Besides ERK, we further investigated whether other members of the mitogen activated protein (MAP) kinase family, including

SAPK/JNK and p38 (stress activated protein kinase 2), are also activated by VEGF. IL-6 activates STAT 3, which mediates antiapoptotic effects in MM cells,^{34,35} and we therefore also tested whether VEGF activates the STAT 3 pathway. Neither p38 and SAPK/JNK nor STAT3 were phosphorylated in MM cells triggered by VEGF (data not shown). Taken together, these data show that VEGF triggers ERK, but not p38, SAPK/JNK, and STAT 3 signaling in MM cells.

VEGF-induced proliferation of MM cells is inhibited by a MEK-1 inhibitor

Maximal stimulation of proliferation of MM.1S cells was observed at VEGF concentrations of 100 ng/mL and 1000 ng/mL, respectively (Figure 2A). To support the functional importance of the ERK pathway in mediating tumor cell proliferation, we measured [³H] thymidine incorporation in these cells triggered by VEGF in the presence or absence of the MEK-1 inhibitor PD98059 (25 μ M). Treatment with PD98059 alone did not inhibit basal MM cell proliferation (Figure 6); however, VEGF-triggered increases in DNA synthesis in MM.1S cells were inhibited by PD98059. In contrast, the PKC inhibitor BIM (2 μ M) did not block proliferation. As a further proof that proliferation is PKC independent, we next determined whether VEGF-induced ERK activation is abrogated by the blockade of PKC. We assayed ERK activation induced by 100 ng/mL VEGF₁₆₅ in MM.1S, as well as patient PCL cells, in the presence or absence of 2 μ M of the PKC inhibitor BIM. The inhibition of PKC did not block VEGF-induced MEK-1-ERK signaling (data not shown). Taken together, these data suggest that proliferation is transduced via MEK-1, but not via PKC, cascades.




Figure 4. Effect of VEGF on the Raf-MEK-ERK pathway. (A) MM.1S cells were starved overnight in RPMI 1640 with 1% FBS and for 3 hours in RPMI 1640 with no FBS. After stimulation of MM.1S cells with 100 ng/mL VEGF₁₆₅ for 5 minutes, Flt-1 immunoprecipitates (IP) from whole cell lysates were analyzed by Western blotting with the use of antisera against phospho-tyrosine residues. Equal loading was confirmed by immunoblotting with antisera directed against Flt-1, and whole cell lysate of VEGF-stimulated HUVECs was similarly immunoblotted as a positive control. Nonspecific protein binding and detection were excluded by incubating protein A-Sepharose (PAS) beads with lysis-buffer and Flt-1 antibody only (control). (B) MM.1S, patient MM, and patient PCL cells, pretreated as described in panel A, were stimulated with 100 ng/mL VEGF₁₆₅ for 5 minutes, 15 minutes, and 45 minutes. Whole cell lysates (40 μ g) were analyzed by Western blotting with antisera against phospho-ERK (pERK). Immunoblotting for ERK-2 confirmed equal protein loading. (C) Densitometry was used to quantitate pERK activity in panel B. The data shown are representative of 3 separate experiments.




Figure 5. Inhibition of VEGF-triggered ERK activation by blockade of VEGF and MEK-1. MM.1S and patient MM cells pretreated as described in Figure 4A were either stimulated with 100 ng/mL VEGF₁₆₅ alone (panel A) or treated for 30 minutes with 30 μg/mL anti-human VEGF antibody (anti-VEGF) (panel B) or for 1 hour with 50 μM PD89059 (panel C) prior to VEGF stimulation. Cells were solubilized, and whole cell lysates (40 μg) were analyzed by Western blotting with antisera against dually phosphorylated MAPK (ERK-1, ERK-2). Equal loading was confirmed by immunoblotting the membranes with antisera against ERK-2.

VEGF-triggered migration of MM and PCL cells is PKC dependent

The involvement of PKC in migration was next investigated. Growth-factor-deprived MM.1S cells were preincubated at 37°C for 60 minutes with BIM and then tested for their ability to migrate in the presence of those VEGF concentrations shown to trigger maximal migration (Figure 3). Figure 7A shows that PKC blockade with BIM, but not MEK-1 blockade with PD89059, abrogates migration in MM.1S cells. Similar results were observed in IM-9 MM cells (data not shown). The abrogation of VEGF-induced migration by BIM (5 and 50 ng/mL) was subsequently also demonstrated in patient PCL cells (Figure 8B). These results indicate the presence of VEGF-induced PKC-dependent, but ERK-independent, migration.




Figure 6. MEK-1 dependency of VEGF-induced proliferation. MM.1S cells were starved for 3 hours in RPMI 1640 with 5% FBS. Cells were incubated with 100 or 1000 ng/mL VEGF₁₆₅ with or without PD98059 (25 μM) or BIM (2 μM). For the last 9 hours of 72-hour cultures, 0.5 μCi [³H] thymidine was added, and radioactivity incorporated into DNA was determined by scintillation counting (Wallac Trilux Betaplate scintillation counter) of automatically harvested cells (Tomec Harvester 96 Mach III). Results are expressed as fold-proliferation of untreated cells (control). The data are means of 3 wells, and the experiment was repeated twice.





Figure 7. PKC dependency of VEGF-induced migration. Growth-factor-deprived MM.1S cells (panel A) were pretreated with or without BIM or PD89059, plated on a polycarbonate membrane (8-μm pore size) in a modified Boyden chamber, and exposed for 4 hours to VEGF (0.5 and 5 ng/mL) added to the lower chamber. At the end of the treatments, cells on the lower part of the membrane were counted with a Coulter counter ZBII. Growth-factor-deprived patient PCL cells (panel B) were pretreated with BIM, and migration induced by VEGF (5 or 50 ng/mL) was analyzed as described above. Results are expressed as the fold migration of untreated cells (control). Representative results from 2 separate experiments are shown.

Discussion

This study shows that VEGF, in addition to its known stimulation of BM angiogenesis, also has direct effects on MM cells. As a model system, we used the MM.1S MM cell line, as well as patient MM and patient PCL cells. Our studies suggest that VEGF stimulates proliferation and migration of MM cells in both autocrine and paracrine mechanisms (Figure 8). Within the BM, VEGF is produced by both MM cells and BMSCs.^{18,19} IL-6 secreted by BMSCs enhances the production and secretion of VEGF by MM cells; conversely, VEGF secreted by MM cells enhances IL-6 production by BMSCs.¹⁹ Binding of MM cells to BMSCs enhances both IL-6 and VEGF secretion. Our studies show that VEGF directly triggers growth and migration of MM cells via the Raf-1–MEK-1–ERK cascade and a PKC-dependent, ERK-independent pathway, respectively.

Our studies first demonstrated that VEGF is produced and secreted by MM cells, suggesting an autocrine VEGF loop in MM. Many hematopoietic tumor cell lines, as well as freshly isolated hematological tumor cells including MM cells, have been reported to produce and secrete VEGF,^{18,19,41,42} consistent with an autocrine VEGF pathway. Our previous studies have demonstrated that IL-6 production by BMSCs is stimulated by the adhesion of MM cells,⁴³⁻⁴⁵ and more recent studies show increased VEGF secretion in BMSCs after tumor cell binding. Adhesion of MM cells to BMSCs would therefore enhance the VEGF autocrine loop. VEGF

Figure 8. VEGF-mediated proliferation and migration of MM cells. VEGF stimulates proliferation and migration of MM cells in a paracrine and autocrine pathway. Within the bone marrow, VEGF is produced by both MM cells and BMSCs. IL-6 secreted by BMSCs enhances the production and secretion of VEGF by MM cells. Conversely, VEGF secreted by MM cells enhances IL-6 production by BMSCs. Binding of MM cells to BMSCs increases both IL-6 and VEGF secretion. Besides stimulating angiogenesis in the BM, VEGF directly triggers cell growth and migration of MM cells via the Raf-1–MEK-1–ERK cascade and a PKC-dependent ERK-independent pathway, respectively.



stimulates IL-6 in BMSCs,^{18,19} suggesting that VEGF produced by MM cells can augment IL-6 secretion by BMSCs, thereby also augmenting MM growth and survival indirectly.

Our studies first showed the expression of VEGF₁₂₁ (516 bp), VEGF₁₄₅ (588 bp), and VEGF₁₆₅ (165 bp) isoforms in MM.1S, patient MM cells, and patient PCL cells, respectively. Interestingly, we could also detect VEGF₁₄₅, a rarely expressed and sparsely studied VEGF form recently found in PELs and prostate cancer.¹² Whether the expression of this splice form plays a role in the pathogenesis of MM is unknown. We next investigated the secretion of VEGF by these cells. MM.1S, patient MM cells, and patient PCL cells secrete VEGF in the range of 100 to 1000 pg/mL (Figure 1B). Taken together, these data show that VEGF is produced and secreted by MM.1S, patient MM, and patient PCL cells and suggest both paracrine and autocrine VEGF-mediated effects on MM cells.

MVD has been observed in the BM of MM patients with disease progression and poor prognosis.²⁰⁻²² In this report we found additionally (1) that VEGF induces modest increments in proliferation in MM.1S and patient MM cells and (2) that VEGF triggers migration of MM.1S and patient PCL cells. Interestingly, maximal activation of migration was much higher in patient PCL than in MM.1S cells, suggesting an important role of VEGF in the transition of MM to PCL. The complex phenomenon of cell migration involves both cytoskeleton-regulated cell motility and cell adhesion,⁴⁶ and in ongoing studies we are examining the differential expression of proteins in MM and PCL cells that are associated with these functions.

These data are also consistent with recent observations that VEGF not only has effects on endothelial cells, but also triggers biological responses in tumor cells. For example, VEGF appears to be a critical cytokine modulating the growth (approximately 3-fold) and spread of Kaposi sarcoma cells.⁴⁷⁻⁵² Additionally, VEGF has been shown to increase proliferation (approximately 2-fold) and migration of leukemic cells.⁵³ The presence of VEGF receptors on hematologic malignancies, as well as these actions on tumor cells triggered by VEGF, may indicate its important role in hematologic malignancies including MM. When coupled, these data strongly indicate a role of VEGF in tumor cells in general and in MM cells in particular.

Having demonstrated these distinct biological sequelae of VEGF in MM cells, we began to delineate the responsible signaling pathways. VEGF mediates its activity mainly via 2 receptor

tyrosine kinases (RTKs): Flt-1⁵⁴ and KDR.⁵⁵ These VEGF-RTKs, which bind VEGF, are single-pass transmembrane receptors with 7 immunoglobulinlike loops in the extracellular domain.⁵⁶ Although Flt-1 has been found on several hematopoietic tumor cell lines, to date neither KDR nor Flt-1 has been identified on MM cells.¹⁸ We found the high-affinity VEGF receptor Flt-1 in MM.1S; in contrast, KDR transcript and protein expression were not detected by RT-PCR and immunoprecipitation, respectively. Activation of VEGF-RTKs occurs through ligand binding, which facilitates receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic portion. By immunoprecipitating cell lysates with Flt-1 antibody, we subsequently showed that VEGF triggered tyrosine-specific phosphorylation of the receptor. Interestingly, further supporting the activation of Flt-1 by VEGF, phosphorylation was also seen in coimmunoprecipitated proteins (data not shown). Studies are presently underway to define these proteins and delineate their function. RT-PCR analysis confirmed expression of Flt-1 comparable to that in MM.1S cells in patient MM cells and patient PCL cells (data not shown). Owing to a restricted number of these cells, we were not able to extract sufficient protein to perform biochemical studies similar to those in MM cell line MM.1S cells. Although the present report shows the expression and activation of Flt-1 in MM.1S cells, recent studies have found either no or only weak expression of Flt-1 and KDR on MM cell lines and primary cells.^{18,19} It therefore remains possible that an additional biologically active VEGF receptor, distinct from Flt-1 and KDR or of mutant forms of these RTKs, is expressed on MM cells.

To characterize downstream signaling molecules, we first investigated whether VEGF activated the ERK pathway in MM cells. The activation of ERK-1 and ERK-2 mediates DNA-synthesis.^{31,32} In time-course experiments using VEGF₁₆₅, specific phosphorylation of ERK-1 and ERK-2 was observed in MM.1S, patient MM, and patient PCL cells. Although cascades activated by VEGF are similar, activation kinetics varied in those cells. Phosphorylation was inhibited by pretreatment with anti-human VEGF antibody, confirming selective ERK activation by VEGF. ERK phosphorylation was also inhibited by pretreatment with MEK-1 inhibitor PD89059, also implicating MEK-1 in the VEGF signaling cascade of MM cells. In addition, we observed VEGF-induced electrophoretic mobility shifting of Raf-1 in MM.1S cells that was inhibited with anti-human VEGF antibody, indicating VEGF-triggered Raf-1 activation. Neither the other prominent MAPK pathways (p38, SAPK) nor the STAT 3 kinase pathway were

activated by VEGF. To support the importance of the ERK pathway in mediating VEGF-triggered DNA synthesis in MM cells, [³H] thymidine incorporation assays using 100 and 1000 ng/mL of VEGF, in the absence or presence of PD89059, were carried out in MM.1S cells. Proliferation induced by VEGF was blocked by PD89059, but not by the PKC inhibitor BIM. Migration of MM as well as of PCL cells induced by VEGF was inhibited by means of the PKC inhibitor BIM but not by PD89059. Importantly, PKC inhibition, in contrast to the MEK-1 inhibition, could not prevent the phosphorylation of ERK-1 and ERK-2. These data indicate the separation of VEGF-induced pathways causing distinct biological sequelae, proliferation through a PKC-independent Raf-1–MEK-1–ERK pathway, and migration through a PKC-dependent pathway.

This study adds another facet to the complex pathophysiological events in the BM micro-environment of MM: VEGF, besides stimulating angiogenesis, has direct effects on MM cells. Moreover, the range of VEGF target cells within the BM compartment of MM is probably even broader. Recently, the ability of VEGF to

inhibit the maturation of dendritic cells⁵⁷ through inhibition of nuclear factor κ B activation was demonstrated.⁵⁸ Further, it was shown that VEGF increases osteoclastic bone-resorbing activity by enhancing their survival.⁵⁹ The direct effects of VEGF on tumor cells, coupled with its effects in the BM micro-environment, suggest VEGF as a target for novel therapies to improve outcome in MM.

Acknowledgments

Dr T. Roberts (Dana-Farber Cancer Institute, Boston, MA) for the gift of phospho-tyrosine and Raf-1 antibodies; Dr D. Frank (Dana-Farber Cancer Institute) for the gift of phospho-STAT 3 antibody; Ms. G. Young and L. Mazor for their technical assistance; and Dr H. Ludwig (Wilhelminenspital, Vienna, Austria) for helpful discussions.

References

- Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. *Blood*. 1998;91:3-21.
- Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J*. 1999;13:9-22.
- Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. *Curr Top Microbiol Immunol*. 1999;237:41-57.
- Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). *Curr Top Microbiol Immunol*. 1999;237:31-40.
- Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 1989;246:1306-1309.
- Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. *Science*. 1989;246:1309-1312.
- DiSalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor/placenta growth factor heterodimer. *J Biol Chem*. 1995;270:7717-7723.
- Neufeld G, Cohen T, Gitay-Goren H, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. *Cancer Metastasis Rev*. 1996;15:153-158.
- Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. *J Biol Chem*. 1997;272:7151-7158.
- Burchardt M, Burchardt T, Chen MW, et al. Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. *Biol Reprod*. 1999;60:398-404.
- Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. *Clin Sci (Colch)*. 1999;97:303-312.
- Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. *Blood*. 1999;94:4247-4254.
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med*. 1995;1:27-31.
- Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [comment appears in *Nat Med*. 1995;1:117-118]. *Nat Med*. 1995;1:149-153.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell*. 1996;86:353-364.
- Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis [comment]. *Cell*. 1994;79:185-188.
- Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature*. 1993;362:841-844.
- Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. *Cancer Res*. 1999;59:728-733.
- Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. *Blood*. 2000;95:2630-2636.
- Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. *Br J Haematol*. 1994;87:503-508.
- Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. *Blood*. 1999;93:3064-3073.
- Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. *Br J Cancer*. 1999;79:451-455.
- D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A*. 1994;91:4082-4085.
- Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [comments appear in *N Engl J Med*. 1999;341:1606-1609, and *N Engl J Med*. 2000;342:975-976] [published erratum appears in *N Engl J Med*. 2000;342:364]. *N Engl J Med*. 1999;341:1565-1571.
- Raje N, Anderson K. Thalidomide: a revival story [editorial; comment]. *N Engl J Med*. 1999;341:1606-1609.
- Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. *Blood*. 1998;92:2908-2913.
- Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. *Blood*. 1992;79:213-222.
- Shen H, Clauss M, Ryan J, et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. *Blood*. 1993;81:2767-2773.
- Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood*. 1996;87:3336-3343.
- Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. *J Biol Chem*. 1996;271:17629-17634.
- Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. *Proc Natl Acad Sci U S A*. 1995;92:7686-7689.
- Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. *Oncogene*. 1997;15:2169-2177.
- Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. *J Immunol*. 1997;159:2212-2221.
- Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. *Immunity*. 1996;5:449-460.
- Cattlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. *Immunity*. 1999;10:105-115.
- Tai YT, Teoh G, Shima Y, et al. Isolation and characterization of human multiple myeloma cell enriched populations. *J Immunol Methods*. 2000;235:11-19.
- Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. *Proc Natl Acad Sci U S A*. 1997;94:979-984.
- Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. *Exp Hematol*. 1995;23:1040-1048.
- Kundra V, Anand-Apte B, Feig LA, Zetter BR. The

- chemotactic response to PDGF-BB: evidence of a role for Ras. *J Cell Biol.* 1995;130:725-731.
40. Kuzuya M, Kinsella JL. Induction of endothelial cell differentiation in vitro by fibroblast-derived soluble factors. *Exp Cell Res.* 1994;215:310-318.
 41. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. *Blood.* 1997;89:1870-1875.
 42. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. *Int J Cancer.* 1998;78:361-365.
 43. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. *Blood.* 1993;82:3712-3720.
 44. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. *Blood.* 1996;87:1104-1112.
 45. Kim I, Uchiyama H, Chauhan D, Anderson KC. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. *Br J Haematol.* 1994;87:483-493.
 46. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. *Cell.* 1996;84:359-369.
 47. Nakamura S, Murakami-Mori K, Rao N, Weich HA, Rajeev B. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. *J Immunol.* 1997;158:4992-5001.
 48. Samaniego F, Markham PD, Gendelman R, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. *Am J Pathol.* 1998;152:1433-1443.
 49. Weindel K, Marme D, Weich HA. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. *Biochem Biophys Res Commun.* 1992;183:1167-1174.
 50. Sakurada S, Kato T, Mashiba K, Mori S, Okamoto T. Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome. *Jpn J Cancer Res.* 1996;87:1143-1152.
 51. Cornali E, Zietz C, Benelli R, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. *Am J Pathol.* 1996;149:1851-1869.
 52. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. *Cancer Res.* 1999;59:183-188.
 53. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. *J Clin Invest.* 2000;106:511-521.
 54. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science.* 1992;255:989-991.
 55. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. *Biochem Biophys Res Commun.* 1992;187:1579-1586.
 56. Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors: generation of receptor-selective VEGF variants by site-directed mutagenesis. *J Biol Chem.* 1996;271:5638-5646.
 57. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [published erratum appears in *Nat Med.* 1996;2:1267]. *Nat Med.* 1996;2:1096-1103.
 58. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. *J Immunol.* 1998;160:1224-1232.
 59. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. *FEBS Lett.* 2000;473:161-164.